• ثبت نام
    • ورود به سامانه
    مشاهده مورد 
    •   صفحهٔ اصلی
    • نشریات انگلیسی
    • International Journal of Health Policy and Management
    • Volume 7, Issue 12
    • مشاهده مورد
    •   صفحهٔ اصلی
    • نشریات انگلیسی
    • International Journal of Health Policy and Management
    • Volume 7, Issue 12
    • مشاهده مورد
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Impact of “Sambhav” Program (Financial Assistance and Counselor Services) on Hepatitis C Pegylated Interferon Alpha Treatment Initiation in India

    (ندگان)پدیدآور
    Sood, AjitMidha, VandanaHalli, Shivalingappa S.Narang, VikramMahajan, RamitMehta, VarunKaur, KirandeepSurlikar, VijayKanchi, SubodhSingh, Dharmatma
    Thumbnail
    دریافت مدرک مشاهده
    FullText
    اندازه فایل: 
    938.1کیلوبایت
    نوع فايل (MIME): 
    PDF
    نوع مدرک
    Text
    Original Article
    زبان مدرک
    English
    نمایش کامل رکورد
    چکیده
    Background Financial constraints, social taboos and beliefs in alternative medicine are common reasons for delaying or not considering treatment for hepatitis C in India. The present study was planned to analyze the impact of non-banking interest free loan facility in patients affected with hepatitis C virus (HCV) in North India.   Methods This one year observational, retrospective study was conducted in Department of Gastroenterology (January 2012-December 2013), Dayanand Medical College and Hospital Ludhiana, to evaluate the impact of program titled “Sambhav" (which provided non-banking financial assistance and counselor services) on treatment initiation and therapeutic compliance in HCV patients. Data of fully evaluated patients with chronic hepatitis, and/or cirrhosis due to HCV infection who were treated with Peginterferon alfa and ribavirin (RBV) combination during this duration (2012-2013) was collected from patient medical records and analyzed. In the year 2012, eligible patients who were offered antiviral treatment paid for treatment themselves, while in 2013, ‘Sambhav' program was launched and this provided interest free financing by non-banking financial company (NBFC) for the treatment of HCV in addition to free counselor services for disease management. The treatment initiation and compliance rates were compared between the patients (n = 585) enrolled in 2013 who were offered ‘Sambhav' assistance and those enrolled in 2012 (n = 628) when ‘Sambhav' was not available.   Results Introduction of Sambhav program improved the rates of treatment initiation (59% in 2013 vs. 51% in 2012, P = .004). Of the 585 eligible patients offered ‘Sambhav' assistance in 2013, 233 patients (39.8%) applied but 106/233 (45.4%) received assistance. Antiviral therapy was started in 93/106 (87.7%) of these patients, while only 52 (42.5%) of 127 patients whose applications were rejected underwent treatment. Compliance to antiviral therapy also improved with the introduction of ‘Sambhav' program (87.7% vs. 74.1%, P = .001).   Conclusion ‘Sambhav' program had significant impact on the initiation of antiviral therapy by overcoming the financial hurdles. The free counselor services helped to mitigate social taboos and imparted adequate awareness about the disease to the patients. Initiatives like ‘Sambhav' can be utilized for improving healthcare services in developing countries, especially for chronic diseases.
    کلید واژگان
    Sambhav Program
    Hepatitis C
    Pegylated Interferon Gamma
    Treatment Access
    India
    Health Insurance

    شماره نشریه
    12
    تاریخ نشر
    2018-12-01
    1397-09-10
    ناشر
    Kerman University of Medical Sciences
    سازمان پدید آورنده
    Department of Gastroentrology, Dayanand Medical College and Hospital (DMCH), Ludhiana, India
    Department of Internal Medicine, Dayanand Medical College and Hospital (DMCH), Ludhiana, India
    University of Manitoba, Winnipeg, MN, Canada
    Department of Pathology, Dayanand Medical College & Hospital (DMCH), Ludhiana, India
    Department of Gastroentrology, Dayanand Medical College and Hospital (DMCH), Ludhiana, India
    Department of Gastroentrology, Dayanand Medical College and Hospital (DMCH), Ludhiana, India
    Department of Pharmacology, Dayanand Medical College and Hospital, Ludhiana, India
    MSD Pharmaceutical Pvt Ltd, Bandra, India
    MSD Pharmaceutical Pvt Ltd, Bandra, India
    Department of Gastroentrology, Dayanand Medical College and Hospital (DMCH), Ludhiana, India

    شاپا
    2322-5939
    URI
    https://dx.doi.org/10.15171/ijhpm.2018.84
    https://www.ijhpm.com/article_3540.html
    https://iranjournals.nlai.ir/handle/123456789/82129

    مرور

    همه جای سامانهپایگاه‌ها و مجموعه‌ها بر اساس تاریخ انتشارپدیدآورانعناوینموضوع‌‌هااین مجموعه بر اساس تاریخ انتشارپدیدآورانعناوینموضوع‌‌ها

    حساب من

    ورود به سامانهثبت نام

    آمار

    مشاهده آمار استفاده

    تازه ترین ها

    تازه ترین مدارک
    © کليه حقوق اين سامانه برای سازمان اسناد و کتابخانه ملی ایران محفوظ است
    تماس با ما | ارسال بازخورد
    قدرت یافته توسطسیناوب